CollPlant Medical Innovation Meets ESG Action

Based on our revolutionary, plant-based technology for the mass production of recombinant human Type I collagen (rhCollagen), we strive to deliver viable medical solutions that empower the betterment of humanity and environmental sustainability.
Our company is propelled by an unwavering commitment to disruption and to transcending the boundaries of medical innovation to enable sustainable development.

Our Vision

Become the leaders in regenerative medicine, helping people live longer and better and creating improvements in science through our regenerative technology.

Our Mission

Discover, develop, and deliver collagen technology and regenerative-medicine products to improve and
prolong lives.

Our ESG Framework

CollPlant is dedicated to making a positive impact on the planet- from the environment and its people to communities and patients we ultimately serve.

Our rhCollagen production process, based on plant-based genetic engineering, minimizes the need for animal-derived collagen. This method not only reduces the environmental impact of traditional practices but also supports ethical and sustainable production.

Our ESG strategy is committed to sustainable business practices, prioritizing current and future societal and environmental needs while upholding ethical conduct.

Our ESG Pillars in Practice

Impact on the Planet

We work to promote powerful human health outcomes, driven by our commitment to sustainability for the planet.

Plant-Based Animal Alternative Solutions

Minimizes the need for animal-derived collagen, reducing animal reliance and promoting ethical medical development.

Reduced land usage

By producing collagen from plants instead of animals, we reduce the land required for collagen production, thereby minimizing the strain on natural resources.

No-Till Farming

By practicing conservation tillage, we promote soil health and prevent erosion, reducing the need for fossil fuel-powered machinery while retaining carbon in the soil. The result is minimized greenhouse gas emissions, embracing climate action.

Minimizing chemical applications

Through our Integrated Pest Management (IPM) program for environmental and biological pest control.

Impact on People

We firmly believe a sustainable healthcare and medicine future begins with safer and healthier treatments, positively impacting patient safety, health, and quality of life.

Healthier and safer collagen derived from tobacco
leaves with bio-functionality that leads to faster tissue repair and does not elicit an immune response leading to tissue rejection

Ensuring a sustainable quality of life our 3D bioprinted breast implants offer a safer and regenerative alternative for augmentation and reconstruction. They provide long lasting performance, aim to reduce waste, and improving patients’ quality of life.

Solving unmet medical needs by utilizing patient cells
in our innovative gut tissue model technology to enable personalized therapeutic response and drug screening for ulcerative colitis therapy. This approach addresses pressing unmet medical needs and drives innovation in less commonly prioritized medical conditions.

Establishing a sustainable demand for tobacco plants in collagen production opens up new economic opportunities for regions historically reliant on tobacco farming. This initiative fosters economic growth and diversification.

Impact on Business Conduct

We conduct our business according to corporate governance and high ethical standards, enabling innovation-driven medical progress through partnerships and a sustainable supply chain.

Our approach emphasizes ethical medical development, focusing on improving animal welfare in medical testing by adhering to the 3 Rs – Replacement, Reduction, and Refinement.

We minimize animal testing in preclinical trials using Finite Element Analysis (FEA), a simulation technique that assesses product design under real-world conditions, thereby reducing our reliance on animal trials.

Support for the United Nations’ Sustainable Development Goals (SDGs)

CollPlant joins the global efforts to support the United Nations’ Sustainable Development Goals and has set out a commitment to furthering efforts to promote SDGs 3,9,12, and 17.
We have chosen to focus on those goals where we have the most significant potential impact and that contribute to the growth of our business.

Aligned with the UN Global Compact

As of August 2023, CollPlant is an official signatory of the UN Global Compact.
CollPlant is committed to the Ten Principles of the United Nations Global Compact, which includes our promise to treat all workers with respect and dignity, ensure safe working conditions, and conduct environmentally responsible, ethical operations.

The UN Global Compact is a voluntary initiative that encourages businesses and organizations to align their strategies and operations with ten universally accepted principles in the areas of human rights, labor, environment, and anti-corruption.

® 2020 CollPlant Biotechnologies Ltd. All rights reserved. Version: CPW 02-23